Boston Immune Technologies & Therapeutics (aka BITT) is structured around developing multiple antagonist antibodies derived from the DOMab platform for indications in oncology, inflammation, autoimmunity and infectious disease. A privately held developer of novel tumor necrosis factor (TNF) Superfamily antagonist antibodies. BITT is initiating clinical trials for BIR2101, its lead candidate - a monoclonal antibody targeting tumor necrosis factor receptor 2 (TNFR2). BITT is also developing additional TNF superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology.
